Healthcare
Johnson & Johnson(JNJ)
Data coverage status · 7 need attention
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T22:29:53.001245Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T22:41:42.67136Z
Fundamentals through 2025-12-31 · Stale
Fundamentals synced 2026-08-05T21:39:48.519888Z
Forecasts: Stale
Forecasts synced 2026-04-28T01:48:30.601297Z
Ownership through 2025-12-31 · Stale
Ownership synced 2026-08-05T21:39:48.519888Z
Short interest through 2025-12-31 · Stale
Short interest synced 2026-08-05T21:39:48.519888Z
News through 2026-05-21T04:31:35Z · Stale
News synced 2026-05-21T08:50:04.813249Z
Company profile: Delayed
Company profile synced 2026-05-01T03:44:15.887523Z
Regular-session price
Offline$257.59($255.00 after-hours, +0.02%)
+1.04% regular session
1Y Change
+49.30%
Window
Aug 5, 2025 → Aug 4, 2026
- Market Cap
- $548.73B
- P/E
- 26.5
- Trailing
- 52W Range
- $162.78 - $274.90
- Volume
- 6.44M
- 0.5x RVOL
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+1.0%
1M
-1.7%
6M
+8.7%
YTD
+22.9%
1Y
+49.3%
- Market Cap
- $548.73B
- NYSE
- P/E
- 26.5
- Trailing valuation
- Revenue Growth
- +6.0%
- TTM growth
- EPS Growth
- +90.5%
- TTM earnings growth
- Operating Margin
- 27.2%
- TTM profitability
- Forward P/E
- —
- Waiting on consensus EPS
- Next Earnings
- Oct 15, 2026
- In 71 days
- 52W Position
- 85%
- $162.78 - $274.90
- Volume
- 0.5x
- 6.44M shares latest
- Benchmark
- +26.47 pts
- vs SPY over 1Y
- Dividend
- 2.3%
- Last ex-date May 26, 2026
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Johnson & Johnson (JNJ) is a Healthcare stock with listed on NYSE. The stock last traded around $257.59 and up 49.3% across the available one-year price window (Aug 5, 2025 → Aug 4, 2026). Baseline metrics include revenue growth of +6.0%, EPS growth of +90.5%, a dividend yield of 2.3%. What stands out right now is revenue +6.0%, EPS +90.5%, free cash flow +6.9% with operating margin 27.2% and ROIC 13.6%. The dividend is present but secondary, with a yield around 2.3%. Valuation sits in the middle of the pack at P/E 26.5 and price/sales 5.7. Stock Foundry combines JNJ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.0% vs +7.6% peer median
Operating Margin
Above sector median
+27.2% vs +19.7% peer median
P/E
Below sector median
26.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q3 2026 was reported on Jul 15, 2026 with an EPS surprise of +1.8%.
The operating story is still moving forward
Revenue is running at +6.0% and EPS at +90.5%, with operating margin around 27.2%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 15, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Delta | 1D | 5D | 20D |
|---|---|---|---|---|
Q3 2026 Jul 15, 2026 | +1.8% | +1.2% | +3.5% | -- |
Q2 2026 Apr 14, 2026 | +0.7% | -0.6% | -5.8% | -6.6% |
Q1 2026 Jan 21, 2026 | +0.0% | +0.2% | +4.5% | +13.3% |
Benchmark Edge
JNJ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
Mixed setup vs SPY
JNJ is 26.47 pts ahead over the shared 1Y window.
JNJ had 1.83 pts deeper max drawdown than SPY.
JNJ beat SPY in 2 of 2 calendar years shown and trailed in 0.
JNJ
+49.30%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
+26.47 pts
Relative to SPY
JNJ Max Drawdown
-10.96%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JNJ and SPY.
| Year | JNJ | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +22.94% | +12.67% | +10.27 pts | JNJ |
| 2025 | +21.18% | +9.40% | +11.78 pts | JNJ |
Company Overview
Johnson & Johnson
New York Stock Exchange
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
- Leadership
- Joaquin Duato
- IPO Date
- Jan 2, 1943
- Employees
- 138.1k
- Street Address
- One Johnson & Johnson Plaza
- Mailing
- New Brunswick, NJ, 08933
- Region
- New Brunswick, NJ, US
- Reporting Currency
- USD
- Investor Line
- 732 524 0400
- Last Updated
- May 1, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 26.5
- EV/EBITDA
- 17.2
- Price/Sales
- 5.7
- Price/Book
- 6.9
Growth
- Revenue
- +6.0%
- EPS
- +90.5%
- Free Cash Flow
- +6.9%
Profitability
- Gross Margin
- 67.9%
- Operating Margin
- 27.2%
- Net Margin
- 28.5%
- ROE
- 26.3%
- ROIC
- 13.6%
Balance Sheet
- Debt/Equity
- 0.22
- Current Ratio
- 0.47
Ownership & Float
- Float
- 2.41B
- Short Interest
- 1.3%
- Insider Owned
- 0.0%
- Institutional Owned
- 76.8%
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.